Keywords: novartis, everolimus, reduces, risk, rcc, progress, benefit

Novartis' everolimus reduces risk of RCC progress 70%; benefit over Nexavar/Sutent

Article | 26 May 2008

Print This

Novartis' RAD001 reduced the risk of disease progression 70% in advanced kidney cancer patients, according to Phase III trial data that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in